Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Other Routine +

Knight Therapeutics Announces Repayment of Revolving Credit Facility

Debt-free balance sheet achieved ahead of schedule, but the credit win was already telegraphed by Q1 cash flow and priced into the +11% run-up.

By The Northwire Desk — AI Analysis Jun 17, 2026 · 17:30 GUD · 9.31 KNIGHT THERAPEUTICS INC.
Executive Summary
  • Knight Therapeutics has fully repaid the US$60 million drawn from its revolving credit facility with the National Bank of Canada and a syndicate of lenders.
  • The repayment was completed within one year of the initial draw, which was originally secured to finance the acquisition of Paladin Pharma.
  • The debt was retired using strong operating cash flows from its Canadian and Latin American operations.
  • The company restores full US$200 million credit capacity for future strategic initiatives, including the US$100 million base facility plus the US$100 million accordion feature.
Material Impact
  • The news is Routine - Positive. The debt repayment is a clear operational win, confirming management's deleveraging plan and validating the Q1 cash flow surge. However, it was fully telegraphed by Q1's $40.7M operating cash flow and prior commentary about repaying $10M in Q1 and April. The stock's +11.3% run into the print shows the market already anticipated this credit improvement. There is no new catalyst here to re-rate the business.
GUD · Price
Company Overview
  • Knight Therapeutics is a specialty pharmaceutical company focused on commercializing branded and generic products across Canada and Latin America.
  • Portfolio includes oncology (Minjuvi, Pemazyre, Bapocil), infectious disease (Ambisome), and women's health (Myfembree, Orgovyx).
  • Growth strategy relies on M&A (Paladin, Sumitomo), regulatory approvals in LATAM, and strategic MOH contracts, particularly in Brazil.
Read the original news release →

More from KNIGHT THERAPEUTICS INC.

Jun 05, 2026 · 18:00

Knight Announces Early Warning Filing Regarding Shares of Crescita

M&A / Property May 27, 2026 · 18:00

LATAM Expansion Validates Growth Strategy But FX and Generic Risks Loom

Other May 08, 2026 · 06:30

Knight Therapeutics scores Brazilian approval for TAVALISSE just as record sales lift stock to all‑time high

Regulatory May 07, 2026 · 06:30

Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

Earnings Mar 19, 2026 · 07:30

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Earnings Mar 17, 2026 · 17:30

Knight wins Anvisa approval for Minjuvi use in Brazil

Regulatory